Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motolimod and Nivolumab in Resectable Head and Neck Cancer
NCT03906526Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Jul 2019
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of motolimod in squamous cell carcinoma of the head and neck (HNSCC) (4 arms), sponsored by Celgene Corporation. Primary endpoint: Numbers of CD8+ T cells within the tumor at Day 52. Started Jul 2019; status: terminated.
02
Drugs
motolimod
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03906526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03906526.